How well are we doing in secondary prevention after myocardial infarction – The STABILITY study experience
Compliance with preventive medications after myocardial infarction is known to be suboptimal in New Zealand (NZ), and to worsen over time. Patients who participate in clinical trials may have better compliance and risk factor control. This study describes achievement of standard of care goals in NZ participants compared to those from the rest of the world in the global STABILITY study. This study evaluated the effects of darapladib on top of best care on cardiovascular death, MI and stroke in high risk patients with established cardiovascular disease.
R. Stewart, J. Benetar, A. Hamer, D. Scott, G. Devom, H. Hart, J. Elliott, J. Tisch, L. Davidson, M. Hills, N. Harrison, R. Rankin, T. O’Meeghan, V. Chen, H. White
Resource Library Item
This resource is available for registered members of CSANZ.
Click the button below to log in to HeartOne and access this resource. Please note that CPD credit is NOT automatically assigned for accessing resources directly.